# TAK-279 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tak-279

> The next catalyst for TAK-279, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Aug to Nov 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TAK-279 |
| Codes | TAK-279 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Plaque Psoriasis](https://sec-api.dev/indications/plaque-psoriasis), Generalized Pustular Psoriasis |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### October 17, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Generalized Pustular Psoriasis; Erythrodermic Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06323356 (A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-11-04." https://clinicaltrials.gov/study/NCT06323356

### November 4, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Generalized Pustular Psoriasis; Erythrodermic Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06323356 (A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-11-04." https://clinicaltrials.gov/study/NCT06323356?tab=results

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06550076 (A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-05 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06550076

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06550076 (A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-05 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06550076

## Same indication

- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib) (ALMS)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tak-279.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TAK-279 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tak-279

```bibtex
@misc{secapidev_pdufa_tak_279_20261116,
  title        = {TAK-279 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tak-279}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tak_279_20261116","title":"TAK-279 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tak-279","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
